HEB Insider Trading Activity and SEC Form 4 Filings
HEB insider trading summary
No open-market insider purchases or sales of Hemispherx Biopharma Inc (HEB) have been reported on SEC Form 4 in the past 12 months.
Latest HEB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 27, 2019 | Thomas K. Equels | Exec. Vice Chairman/CEO/Pres. | Buy | $12K (2,632 @ $4.37) |
| Jun 21, 2019 | Wayne S Springate | Sr. VP of Operations | Buy | $21K (5,211 @ $4.03) |
| Jun 21, 2019 | Peter W. Rodino III | Dir Govt Relations/Sectry | Buy | $35K (8,695 @ $4.03) |
| Jun 21, 2019 | David R Strayer | Chief Science/Medical Officer | Buy | $10K (2,481 @ $4.03) |
| Jun 21, 2019 | Stewart Appelrouth | Director | Buy | $39K (9,677 @ $4.03) |
| Jun 21, 2019 | Thomas K. Equels | Exec. Vice Chairman/CEO/Pres. | Buy | $118K (29,404 @ $4.03) |
| Jun 21, 2019 | William M Mitchell | Director | Buy | $39K (9,677 @ $4.03) |
| Mar 19, 2019 | Thomas K. Equels | Exec. Vice Chairman/CEO/Pres. | Buy | $2K (13,400 @ $0.18) |
| Nov 30, 2018 | Thomas K. Equels | Exec. Vice Chairman/CEO/Pres. | Buy | $463 (2,400 @ $0.19) |
| Nov 30, 2018 | Thomas K. Equels | Exec. Vice Chairman/CEO/Pres. | Buy | $1 (5 @ $0.19) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.